Medical Products Support and Advanced Concept Development
Abstract
Guidance for Development of the Force (GDF) - Medical Products Support and Advanced Concept Development: Funding supports (1) advanced concept development of medical products that are regulated by the US Food and Drug Administration (FDA), (2) clinical and field validation studies supporting the transition of FDA-licensed and unregulated products and medical practice guidelines to the military operational user,(3) prototyping, (4) risk reduction and product transition efforts for medical information technology applications such as coordination with the Program Execution Office for possible integration into the Military Health System, and (5) medical simulation and training system technologies. This portfolio is designed to address areas of interest to the Secretary of Defense related to Wounded Warriors, capabilities identified through the Joint Capabilities Integration and Development System, and the sustainment of priority investments in science, technology, research, and development, as stated in the Quadrennial Defense Review. Program development and execution is peer-reviewed and fully coordinated with all of the Military Services, appropriate Defense agencies or activities, and other federal agencies such as the Department of Veterans Affairs, the Department of Health and Human Services, and the Department of Homeland Security. Coordination occurs through the planning and execution activities of the Defense Health Agency’s Joint Program Committees (JPC), which were established to manage research, development, test and evaluation for Defense Health Program (DHP) sponsored research. Research within this program element encompasses Medical Simulation and Information Sciences (through JPC-1), Military Infectious Disease (through JPC-2), Military Operational Medicine (through JPC-5), Combat Casualty Care (through JPC-6), and Clinical and Rehabilitative Medicine (through JPC-8). As the research efforts mature, the most promising efforts will transition to medical products and support systems development funding, Program Element 0605145. For the Air Force Medical Service, funding in this program element supports technology development for the rapid transition of medical products and capabilities from Air Force laboratories, and the ability to perform modifications /enhancements required to integrate commercial off-the-shelf (COTS) and near-COTS products into the military operating environment. Ability to enhance or modify existing COTS is a cost effective technique we should maximize where possible, ensuring warfighters have appropriate technology at hand to care for wounded at the point of injury through definitive care and on to rehabilitation and reintegration at the most efficient cost and schedule possible. Significant benefits can be obtained from rapid insertion of high value / impact technologies into healthcare operations to address capabilities that enter the acquisition life-cycle at high TRL levels that can readily be implemented with significant upside potential. Cannot ensure viability of S&T and translational research efforts with a materiel component without correctly programmed funding for logical progression and transition of those activities in the product development lifecycle. Ensures viability of S&T and translational research efforts with a materiel component by providing programmed funding for logical progression and transition of those activities in the product development lifecycle. The Army Medical Command received DHP Congressional Special Interest (CSI) research funding focused on Peer-Reviewed Traumatic Brain Injury/ Psychological Health, and Peer-Reviewed Joint Warfighter Medical Research. The Uniformed Services University received CSI funding for the Therapeutics Service Dog Training Program. Because of the CSI annual structure, out-year funding is not programmed.
Document Details
- Document Type
- R2 Budgetary Justification
- Publication Date
- Oct 01, 2016
- Source ID
- 0604110HP_2_0130_PB_2016
- Change Summary Explanation
- FY 2014: Realignment from Defense Health Program, Research, Development, Test and Evaluation (DHP RDT&E), PE 0604110-Medical Products Support and Advanced Concept Development (-$11.041 million) to DHP RDT&E PE 0605502-Small Business Innovation Research (SBIR) Program (+$11.041 million). FY 2014: Congressional Special Interest (CSI) Additions to DHP RDT&E, PE 0604110-Medical Products Support and Advanced Concept Development (+$49.000 million). FY 2014: Federally Funded Research and Development Center Reduction, PE 0604110-Medical Products Support and Advanced Concept Development (-$0.124 million). FY 2015: Federally Funded Research and Development Center Reduction, PE 0604110-Medical Products Support and Advanced Concept Development (-$0.173 million). FY 2015: Congressional Special Interest (CSI) Additions to DHP RDT&E, PE 0604110-Medical Products Support and Advanced Concept Development (+$53.208 million). FY 2016: Realignment from Defense Health Program, Research, Development, Test and Evaluation (DHP RDT&E), PE 0603115-Medical Technology Development (-$4.000 million) to DHP RDT&E PE 0604110-Medical Products Support and Advanced Concept Development (+$4.000 million). FY 2016: Realignment from Defense Health Program, Research, Development, Test and Evaluation (DHP RDT&E), PE 0605145-Medical Products and Support System Development (-$3.628 million) to DHP RDT&E PE 0604110-Medical Products Support and Advanced Concept Development (+$3.628 million).
- Service Agency Name
- Defense Health Program
Related Documents
- Child Project: GDF-Medical Products Support and Advanced Concept Development
- Child Accomplishment: GDF – Medical Product Support and Advanced Concept Development
- Child Project: CSI - Congressional Special Interests
- Child Project: Medical Products Support and Advanced Concept Development (AF)
- Child Accomplishment: Medical Products Support and Advanced Concept Development (AF)